Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS Miss
Tweet Send to a Friend
Cantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
